Isofol Medical AB (publ) invites to an audiocast on December 6 at 08.00 a.m. CET
GOTHENBURG, Sweden, December 5, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced on December 3 that the ongoing […]
Corporate Information
Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision
GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and
Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)
GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and
Isofol appoints nomination committee ahead of the Annual General Meeting 2022
GOTHENBURG, Sweden, November 19, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Trading in Isofol’s shares commences today on Nasdaq Stockholm
GOTHENBURG, Sweden, October 21, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol Medical AB (publ) intends to list its shares on Nasdaq Stockholm
GOTHENBURG, Sweden, October 15, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the
Company presentation at LSX Nordic Congress 2021
From September 7-17 Isofol participated in LSX Nordic Congress, an opportunity for 1:1 meetings with Nordic life science executives focused
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021
Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), held
Isofol completes recruitment of Japanese patients in the global phase III AGENT study
GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market:
Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that